New Noninvasive Biomarkers for the Diagnosis and Treatment of Pancreatic Disorders
Abstract
There is no clinically applicable mechanism to noninvasively image the insulin producing beta-cells of the pancreas. Individuals only become aware of having developed type I or type II diabetes (T1D or T2D, respectively) following the appearance of over thyperglycemia. Our objective was to utilize advanced high-resolution magnetic resonance spectroscopy (MRS, a form of MRI) to noninvasively measure the small molecule constituents of the pancreas (i.e., define the pancreatic "MRS-ome") in a living large animal model (swine).As a proof-of-principle, we planned to determine whether 2D-MRS can detect the loss of the insulin-producing beta-cells which underlies T1D in a swine. Just after obtaining institutional approval to conduct the animal studies the pandemic hit. Because of the large number of veterinarians and MRI staff needed to anesthetize, monitor vitals, and MRI image large animals, our studies could not be conducted due to limitations on the number of people allowed per square foot. We shifted to improving the imaging parameters to achieve much shorter data acquisition times which will be very helpful for future MRS imaging of live animals.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2021
- Accession Number
- AD1151188
Entities
People
- Daniel L. Kaufman
Organizations
- University of California, Los Angeles